相似文献
1
Questioning the benefits of statins.
CMAJ. 2005 Nov 8;173(10):1210; author reply 1210. doi: 10.1503/cmaj.1050121.
2
Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Nat Clin Pract Cardiovasc Med. 2006 Dec;3(12):664-72. doi: 10.1038/ncpcardio0711.
3
Questioning the benefits of statins.
CMAJ. 2005 Nov 8;173(10):1207; author reply 1210. doi: 10.1503/cmaj.1050120.
4
Lipids, statins and cardiovascular disease.
Climacteric. 2008 Aug;11(4):347-8; author reply 348-50. doi: 10.1080/13697130802242632.
5
[Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
Lakartidningen. 2006;103(35):2462-6.
6
Lipid abnormalities and cardiovascular risk in the elderly.
Curr Med Res Opin. 2008 Mar;24(3):653-7. doi: 10.1185/030079908X273363. Epub 2008 Jan 23.
7
[Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature].
G Ital Cardiol (Rome). 2014 Mar;15(3):149-60. doi: 10.1714/1463.16163.
8
Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Am J Cardiol. 2007 Feb 19;99(4A):133B-140B. doi: 10.1016/j.amjcard.2006.11.014. Epub 2006 Dec 28.
9
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Clin Ther. 2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004.
10
Cholesterol and peripheral vascular disease: a neglected topic?
Scand Cardiovasc J. 2007 Jun;41(3):136-7. doi: 10.1080/14017430701316581.
本文引用的文献
1
The analysis by Manuel and colleagues creates controversy with headlines, not data.
CMAJ. 2005 Apr 12;172(8):1033-4; discussion 1037. doi: 10.1503/cmaj.1041427.
2
The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
CMAJ. 2005 Apr 12;172(8):1027-31. doi: 10.1503/cmaj.1040202.
Zotero 插件